When was Hutchison China MediTech founded?

Hutchison China MediTech was founded in 2005 and raised its 1st funding round 15 years after it was founded.

Where is Hutchison China MediTech located?

Hutchison China MediTech is headquartered in Hong Kong, China.

Who is the current CEO of Hutchison China MediTech?

Christian Hogg of Hutchison China MediTech.

How many employees does Hutchison China MediTech have?

As of Sep 30, 2026, the latest employee count at Hutchison China MediTech is 700.

Is Hutchison China MediTech a funded company?

Hutchison China MediTech is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jun 25, 2020.

When was the latest funding round of Hutchison China MediTech?

Hutchison China MediTech's latest funding was a $***** Post IPO round on Mar 07, 2022, with participation from 1 investor. Its primary sector is Immunology. In China, the Immunology sector has seen $324M in funding in 2026 to date.

Where does Hutchison China MediTech rank among its competitors?

Hutchison China MediTech ranks 236th amongst 3736 active competitors, of which 1229 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Hutchison China MediTech?

Hutchison China MediTech's top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Immuneel secured the most recent funding round in June, 2026.

Hutchison China MediTech - 2026 Company Profile, Team, Funding & Competitors

Hutchison China MediTech is a public company based in Hong Kong (China), founded in 2005. It operates as a Developer of immunotherapies for the treatment of cancer and immunological diseases. Hutchison China MediTech has raised an undisclosed amount in funding. The company has 3736 active competitors, including 1229 funded and 866 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.

Company Details

Developer of immunotherapies for the treatment of cancer and immunological diseases. The company's drugs include Savolitinib, Surufatinib, Fruquintinib, HMPL-523, HMPL-689, HMPL-453, HMPL-306, HMPL-295, and Eptinib. These drugs can be used alone or in combination with other drugs. These drugs are potent oral inhibitors of vascular endothelial growth factor receptors.

Website: hutch-med.com
Social
Email ID: *****@hutch-med.com
Phone Number: +852 **********

Key Metrics

Founded Year

2005

Location

Hong Kong, China

Stage

Public

Latest Funding Round

Post IPO, Mar 07, 2022, $*****

Investors

EQT & 4 more

Ranked

236^th among 3736 active competitors

Employee Count

700 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3450 more

Exit Details

Public

View Hutchison China MediTech's full profile

Hutchison China MediTech got listed on May 19, 2006.

Click here to take a look at Hutchison China MediTech's IPO in detail

Hutchison China MediTech has raised funding over 3 rounds. Its first funding round was on Jun 25, 2020. Its latest funding round was a Post IPO round on Mar 07, 2022 for $*****. 1 investor participated in its latest round. Hutchison China MediTech has 5 institutional investors.

Here is the list of recent funding rounds of Hutchison China MediTech:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 07, 2022	1595238	Post IPO	3617568	6278792	2134403	7265516
Apr 08, 2021	6535692	Post IPO	8588592	8629196	4260293	EQT
Jun 25, 2020	8417321	Post IPO	4671477	3333340	3750602	General Atlantic

Access funding benchmarks and valuations. Sign up today!

View details of Hutchison China MediTech's funding rounds and investors

Hutchison China MediTech's employee count trend

Hutchison China MediTech has 700 employees as of Sep 26. Here is Hutchison China MediTech's employee count trend over the years:

Employee count trend for Hutchison China MediTech

Uncover Hutchison China MediTech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Hutchison China MediTech include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Hutchison China MediTech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	76/100
5th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
236th	Hutchison China MediTech 2005, Hong Kong (China), Public	Developer of immunotherapies for the treatment of cancer and immunological diseases	-	EQT, General Atlantic & 3 others	59/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Hutchison China MediTech's competitors? Click here to see the top ones

Hutchison China MediTech has made no investments or acquisitions yet.

Here is the latest report on Hutchison China MediTech's sector:

Free

Oncology - Sector Report

Edition: September, 2026 (75 Pages)

View all reports related to Hutchison China MediTech

Media has covered Hutchison China MediTech for a total of 50 events in the last 1 year, 24 of them have been about company updates and 2 about people movement.